Our approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, renal ischemia, and myocardial infarction. This pathway, dubbed N2, can trigger a cascade of tissue damaging events leading to loss of organ function. Preclinical proof-of-concept for our antibody therapeutic DeciMab has been demonstrated at clinically relevant points of intervention and the company plans to initiate human safety/tolerability studies in 2017. DecImmune Therapeutics has received financing from HealthCare Ventures, Amgen Ventures, Astellas Venture Management and Broadview Ventures, in addition to $7 million in NIH SBIR grant funding.